The Deng laboratory at CIMR is committed to elucidating the role of B cell heterogeneity in tumor development, metastasis and responses to immunotherapy. Our objective is to achieve a deeper understanding of the pathological mechanism associated B cells and tertiary lymphoid structures in prevalent solid tumors, as well as develop potential therapeutic strategies aimed at reprogramming B cell fate.